跳至主要内容
临床试验/NCT02349711
NCT02349711已完成不适用

Probiotics (Lactobacillus Gasseri KS-13, Bifidobacterium Bifidum G9-1, Bifidobacterium Longum MM-2) and Health-related Quality of Life in Individuals With Seasonal Allergies

University of Florida2 个研究点 分布在 1 个国家目标入组 224 人开始时间: 2015年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
224
试验地点
2
主要终点
Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ

研究概览

简要总结

In this randomized, double-blind, placebo-controlled study, participants with seasonal allergies will receive a daily probiotic or placebo for 8 weeks. Questionnaires will assess health-related quality of life, stress, physical activity, gastrointestinal symptoms, adverse events, and compliance. In a subset of subjects, stool and blood samples will be collected at baseline and at week 6 of the intervention (estimated to be peak allergy season) to characterize microbial communities and immune function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects will be included if they:
  • are 18 to 60 years of age (inclusive).
  • receive a score of 2 or greater on the Mini Rhinoconjunctivitis Quality of Life Questionnaire.
  • are willing and able to complete the Informed Consent Form in English.
  • are available for 8 consecutive weeks to participate in this study.
  • be willing and able to complete online daily and weekly questionnaires regarding general wellness, bowel function, quality of life, gastrointestinal symptoms, and physical activity.
  • are willing and able to maintain their regular level of physical activity and diet for the 8-week study.
  • are able to take the study supplement without the aid of another person.
  • are willing to discontinue consumption of fermented foods or probiotics (e.g., yogurts with live, active cultures or supplements), or immune-enhancing supplements (e.g., Echinacea or fish oil).
  • are willing to provide 2 blood and 2 stool samples (subgroup only).

排除标准

  • Subjects will be excluded if they:
  • do not meet any of the above criteria.
  • use allergy medications, including nasal sprays, 5 or more days per week.
  • receive allergy shots.
  • are currently pregnant or attempting to get pregnant.
  • are currently taking any systemic corticosteroids, androgens (such as testosterone), or large doses of anti-inflammatory drugs (i.e., aspirin in doses >600 mg/d) on a regular basis.
  • are currently being treated for or have any of the following physician-diagnosed diseases or conditions: HIV/AIDS; immune modulating diseases (autoimmune disease, hepatitis, cancer, etc.); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases/conditions such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, or colostomy, but not including GERD; or have a central venous catheter.
  • have received chemotherapy or other immune suppressing therapy within the last year.

结局指标

主要结局

Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ

时间窗: up to 8 weeks from date of randomization

MiniRQLQ, global score (0=not troubled, 6=extremely troubled; an average of the 14 questions; includes all domains)

次要结局

  • Regulatory T Cells (Tregs)(baseline and week 6)
  • Serum Total Immunoglobulin E (IgE)(baseline and week 6)
  • Constipation Symptom Score, Measured by Gastrointestinal Symptom Response Scale (GSRS) Questionnaire(weeks 0, 1, 2, 3, 4, 5, 6, 7)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验